Glycoprotein IIb/IIIa inhibitors in the treatment of thromboembolic events related to endovascular treatment of cerebral aneurysms-systematic review and meta-analysis
- PMID: 36961079
- PMCID: PMC10973825
- DOI: 10.1177/19714009231166090
Glycoprotein IIb/IIIa inhibitors in the treatment of thromboembolic events related to endovascular treatment of cerebral aneurysms-systematic review and meta-analysis
Abstract
Background and aims: Thromboembolism complication is considered the most common complication associated with the treatment of endovascular. This systematic review and meta-analysis aimed to assess the studies investigating the effect of glycoprotein IIb/IIIa inhibitor agents on thromboembolic complications during endovascular aneurysm coiling.
Materials and methods: This systematic review investigated the outcome of the use of three glycoprotein IIb/IIIa inhibitor agents (ie abciximab, tirofiban, and eptifibatide) on the thromboembolic complications during endovascular aneurysm coiling. The electronic databases of PubMed, Web of Science, Scopus, and Medline were searched up to 25 June 2021, using the keywords "Abciximab," "Tirofiban," and "Eptifibatide" incombination with "Thromboembolism Complication," "Aneurysms," and "Endovascular Aneurysm Coiling."
Results: A total of 21 articles were found to be eligible and included in this review. The rates of complete and partial recanalization were estimated to be 56% and 92% in patients who underwent abciximab and tirofiban therapy, respectively. Rupture aneurysms were found in the majority of patients. In general, the mortality rate of the patients treated for thromboembolic complications during endovascular treatment of cerebral aneurysms with glycoprotein IIb/IIIa inhibitors was found to be 4.8% (CI 95%:0.027-0.067; p < .005). The average remission rate in studies investigating thromboembolism was 91% (CI 95%:0.88-0.95, I2 : 65.65/p < .001).
Conclusion: Based on the obtained results, a higher mean rate of complete recanalization by eptifibatide was found in studies in which abciximab or tirofiban were used, compared to other mentioned agents. Moreover, the amount of hemorrhage was reported to be less after using tirofiban rather than abciximab.
Keywords: Abciximab; cerevral aneurysm; eptifibatide; tirofiban.
Conflict of interest statement
Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
-
Glycoprotein IIb/IIIa Inhibitors in Prevention and Rescue Treatment of Thromboembolic Complications During Endovascular Embolization of Intracranial Aneurysms.Neurosurgery. 2018 Mar 1;82(3):268-277. doi: 10.1093/neuros/nyx170. Neurosurgery. 2018. PMID: 28472526 Review.
-
Rescue treatment of thromboembolic complications during endovascular treatment of cerebral aneurysms: a meta-analysis.AJNR Am J Neuroradiol. 2015 Jan;36(1):121-5. doi: 10.3174/ajnr.A4066. Epub 2014 Jul 31. AJNR Am J Neuroradiol. 2015. PMID: 25082819 Free PMC article.
-
Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.Circulation. 2002 Sep 17;106(12):1470-6. doi: 10.1161/01.cir.0000029744.01096.1f. Circulation. 2002. PMID: 12234950 Clinical Trial.
-
Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.J Thromb Thrombolysis. 2001 Apr;11(2):99-110. doi: 10.1023/a:1011216414539. J Thromb Thrombolysis. 2001. PMID: 11406724 Review.
-
Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.Am Heart J. 1999 Oct;138(4 Pt 2):307-16. doi: 10.1053/hj.1999.v138.a100460. Am Heart J. 1999. PMID: 10502236 Review.
References
-
- Aggour M, Pierot L, Kadziolka K, et al. Abciximab treatment modalities for thromboembolic events related to aneurysm coiling. Neurosurgery 2010; 67(suppl_2): ons503–508. - PubMed
-
- Friedman JA, Piepgras DG, Pichelmann MA, et al. Small cerebral aneurysms presenting with symptoms other than rupture. Neurology 2001; 57(7): 1212–1216. - PubMed
-
- Wiebers DO Whisnant JP Huston J, 3rd et al. International Study of Unruptured Intracranial Aneurysms Investigators.. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 2003; 362(9378): 103–110. - PubMed
-
- International Study of Unruptured Intracranial Aneurysms Investigators . Unruptured intracranial aneurysms—risk of rupture and risks of surgical intervention. N Engl J Med 1998; 339(24): 1725–1733. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical